GEA North America LLC ConsiGma standalone Process Analytical Technology (PAT) Rig, or equivalent
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA OFFICE OF ACQ GRANT SVCS
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126Q131715
NAICS
334516 - Analytical Laboratory Instrument Manufacturing
Classification Code
6640
Additional Details
Documents1
The U.S. Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued a combined synopsis/solicitation for the procurement of a GEA North America LLC ConsiGma standalone Process Analytical Technology (PAT) Rig, or an equivalent instrument. This procurement is managed by the FDA Office of Acquisition and Grant Services, and is classified under NAICS code 334516, which pertains to Analytical Laboratory Instrument Manufacturing. The associated Product Service Code is 6640, indicating laboratory equipment and supplies.
The primary objective of this procurement is to acquire a state-of-the-art PAT rig that supports advanced process analytical technology applications. The intended outcome is to enhance the FDA’s analytical capabilities, likely in support of regulatory science, quality assurance, or research initiatives. The solicitation is open to vendors who can provide either the specified GEA ConsiGma PAT Rig or a functionally equivalent system, ensuring flexibility in sourcing while maintaining stringent technical requirements.
Key requirements and deliverables for this opportunity include the provision of a complete PAT rig that meets or exceeds the performance and functional specifications outlined in the attached Request for Quote (RFQ). Vendors are expected to supply all necessary components, installation, and potentially training or support services as detailed in the RFQ documentation. The solution must be suitable for analytical laboratory environments and align with the FDA’s operational standards.
This procurement is not subject to any set-aside restrictions, meaning it is open to all qualified vendors regardless of business size or socioeconomic status. Interested parties should note that the solicitation is being conducted as a combined synopsis/solicitation, streamlining the acquisition process and requiring a comprehensive response by the specified deadline.
The contracting activity is managed by Suzanne Martella, who serves as the primary point of contact for all inquiries related to this notice. She can be reached via email at [email protected] or by phone at 301-796-2383. The solicitation remains active, with the deadline for receipt of quotes extended to June 24, 2026, at 3:30 pm Eastern Time.
Contractors considering this opportunity should review the attached RFQ for detailed technical specifications and submission instructions. The procurement is expected to result in the acquisition of a high-performance analytical instrument that will remain a critical asset for the FDA throughout the contract lifecycle. For further information and to access the solicitation documents, interested vendors are directed to the official notice on SAM.gov at https://sam.gov/opp/89b53c5e8c0d4b01ab27a14f1bf4d849/view.